Drugs / PEGylated Recombinant Human Hyaluronidase (PEGPH20)
PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03281369 | Oct 2017 → Oct 2025 | digestive system carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02910882 | Jan 2017 → Aug 2018 | pancreatic adenocarcinoma | Scripps Health | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGylated Recombinant Human Hyaluronidase (PEGPH20) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02910882 ↗ |
| Modality | Protein / enzyme biologic | “PEGylated recombinant human hyaluronidase (PEGPH20)” NCT03281369 ↗ |
| Route | Intravenous | “Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute” NCT02910882 ↗ |